Pune, India | November 17, 2025
Regeneron Pharmaceuticals announced it will present groundbreaking data in fourteen abstracts at the upcoming ASH 2025 Annual Meeting. The conference, taking place in Orlando, Florida, from December 6 to 9, will emphasize innovations in blood cancer treatment and rare blood disorder therapies. These findings demonstrate Regeneron’s ongoing commitment to hematology drug development and clinical excellence.
One of the most anticipated highlights includes data from Regeneron’s bispecific antibody, Lynozyfic (linvoseltamab-gcpt), which showed promising early clinical results. In the Phase 1/2 LINKER MM4 trial, Lynozyfic was studied as a monotherapy for patients with newly diagnosed multiple myeloma. Notably, this trial is the first to test a BCMA×CD3 bispecific antibody in a frontline myeloma setting. That potentially changes initial treatment strategies.
Additionally, Regeneron will share updated results from its LINKER MM2 study, where Lynozyfic was combined with two different anti-CD38 monoclonal antibodies. This study targeted patients whose multiple myeloma had relapsed or become refractory. These results could redefine treatment approaches during the early stages of disease and offer improved patient outcomes.
Beyond multiple myeloma, Regeneron is making substantial progress in lymphoma research. The company will present findings from its odronextamab program, including an oral session covering the OLYMPIA-3 trial. In this study, odronextamab was given with chemotherapy but without rituximab as a frontline therapy for diffuse large B-cell lymphoma (DLBCL). This approach explores a novel combination that could reduce therapy complexity and maintain efficacy.
Regeneron will also report odronextamab data for follicular lymphoma (FL). Presentations include the OLYMPIA-2 trial for frontline therapy and OLYMPIA-5 for relapsed or refractory disease. In which odronextamab was combined with lenalidomide. These results could expand bispecific antibody applications in first-line lymphoma treatment. That offers patients new therapeutic options earlier in their care journey.
In addition to cancer-focused research, Regeneron is advancing therapies for rare blood disorders. The company will present data on a novel combination of cemdisiran and pozelimab in patients with paroxysmal nocturnal hemoglobinuria (PNH). This head-to-head comparison against ravulizumab could shape future treatment standards for complement-mediated disorders and provide safer, more effective therapy alternatives.
Regeneron’s pipeline also includes first-in-human data for REGN7257, targeting patients with severe aplastic anemia who did not respond to immunosuppressive therapy or relapsed afterward. Early safety and efficacy findings may generate significant interest because of the high unmet medical need within this patient population. Consequently, this therapy could represent a vital advance in treating challenging hematologic conditions.
L. Andres Sirulnik, M.D., Ph.D., Senior Vice President and Head of Hematology Clinical Development at Regeneron, described 2025 as a “landmark year” for the company’s hematology program. He emphasized that oral presentations of Lynozyfic and frontline odronextamab demonstrate how earlier intervention with innovative therapies could benefit a larger patient population.
Sirulnik added that the updated data across Regeneron’s blood disorder portfolio “reinforce our strategy of translating our deep expertise in hematology into meaningful progress where unmet needs remain.” These findings underline the company’s commitment to addressing complex blood diseases through scientific innovation.
To engage investors and other stakeholders, Regeneron will host a virtual “Regeneron Roundtable” on December 10 at 8:30 a.m. ET. The company will share additional insights into its multiple myeloma development program during this session, providing a comprehensive overview of ongoing and upcoming clinical research.
Regeneron’s extensive presence at ASH 2025 reflects its dedication to tackling a broad spectrum of blood cancers and disorders. By leveraging bispecific antibodies, RNA-based therapies, and novel combinations, the company continues expanding treatment possibilities.
If these findings continue to demonstrate early promise, they may fundamentally reshape hematology treatment approaches. Patients with multiple myeloma, lymphoma, PNH, and severe aplastic anemia could gain access to more effective therapies. That improves survival and quality of life.
In conclusion, Regeneron’s ASH 2025 presentations highlight its commitment to clinical innovation, scientific discovery, and improving outcomes for patients suffering from complex hematologic diseases worldwide.
About the Author
